Latest Stories
3 Reasons to Avoid DHR and 1 Stock to Buy Instead
Danaher’s 24.7% return over the past six months has outpaced the S&P 500 by 14.7%, and its stock price has climbed to $234.55 per share. This performance may have investors wondering how to approach the situation.
AXIS Capital (AXS): Buy, Sell, or Hold Post Q3 Earnings?
AXIS Capital trades at $103.18 and has moved in lockstep with the market. Its shares have returned 7.4% over the last six months while the S&P 500 has gained 10%.
3 Reasons to Sell SEMR and 1 Stock to Buy Instead
Over the past six months, Semrush has been a great trade, beating the S&P 500 by 21.4%. Its stock price has climbed to $11.91, representing a healthy 31.4% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
2 Reasons to Watch INSP and 1 to Stay Cautious
What a brutal six months it’s been for Inspire Medical Systems. The stock has dropped 24.3% and now trades at $94.73, rattling many shareholders. This might have investors contemplating their next move.
2 Reasons to Watch ELV and 1 to Stay Cautious
Elevance Health’s 33.1% return over the past six months has outpaced the S&P 500 by 23.1%, and its stock price has climbed to $368.00 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
3 Reasons to Avoid DOV and 1 Stock to Buy Instead
Dover trades at $199.20 and has moved in lockstep with the market. Its shares have returned 6.5% over the last six months while the S&P 500 has gained 10%.
3 Reasons to Avoid TDOC and 1 Stock to Buy Instead
Teladoc’s stock price has taken a beating over the past six months, shedding 26.8% of its value and falling to $6.10 per share. This might have investors contemplating their next move.
Dycom (DY): 3 Reasons We Love This Stock
The past six months have been a windfall for Dycom’s shareholders. The company’s stock price has jumped 42.7%, hitting $366.38 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Arthur J. Gallagher (AJG): 3 Reasons We Love This Stock
Over the past six months, Arthur J. Gallagher’s shares (currently trading at $256.94) have posted a disappointing 16.6% loss, well below the S&P 500’s 10% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.
3 Reasons BDC is Risky and 1 Stock to Buy Instead
Over the last six months, Belden’s shares have sunk to $114.97, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 10% gain. This might have investors contemplating their next move.